PhytoTech Medical Limited
(ASX:PYL) says it has significantly expanded its medical cannabis product portfolio.
The drug discovery group’s latest deal will expand its portfolio through adding five new active pharmaceutical ingredients and hemp-flower extract.
The deal could potential add up to about $30 million in revenue next year, based on the potential production volumes and the value of the extra active pharmaceutical ingredients.
PhytoTech Medical was the first medical marijuana company to list on the ASX in January 2015 and the company believes the latest deal advances its ‘Farm to Pharma’ strategy.
